How PMOS Is Diagnosed: Criteria & Workup Explained

Home / BDKC / How PMOS is Diagnosed Today

Bharat Daftary Knowledge Centre · Diagnosis & Workup

How PMOS is Diagnosed Today

- The Criteria Explained

The three-feature framework used by specialists across the world, the workup that establishes the diagnosis, and what a well-done diagnostic evaluation looks like from start to finish.

By Dr Gautam V. DaftaryDirector, Aksigen IVF

Last reviewed June 202610-minute read2,535 words

PMOS diagnosis is not a single test. It is the recognition of a pattern — a cluster of clinical features that share an underlying biological signature. There is no blood test that says you have PMOS the way there is for pregnancy or diabetes. The diagnosis is made by a clinician who looks at your cycles, your symptoms, your blood work, and your ultrasound together, and recognises the pattern.

The current framework for making that recognition is set out in the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome¹. This is the document that specialists across the world use to decide who has PMOS and who does not. The rename to PMOS in 2026² did not change the diagnostic criteria substantially; the same framework is being carried forward.

This article walks through how a proper PMOS diagnostic evaluation is done — the three core features that define the diagnosis, the workup that establishes it, the exclusion diagnoses that must be ruled out, the phenotypes that describe the different ways PMOS can present, and what to expect from a well-done diagnostic visit. It is written for women being evaluated, or considering being evaluated, and for those who want to understand what has already been done.

The Three Features in Detail

Ovulatory dysfunction means periods that are infrequent, irregular, or absent. Specifically: cycles longer than 35 days, fewer than nine periods a year, or completely absent periods (amenorrhoea). Some women have cycles that appear regular in length but do not consistently produce ovulation — this can be detected by mid-luteal progesterone testing across two or three cycles, or by more detailed cycle monitoring. Post-pubertal women should have established regular ovulatory cycles within 2 to 3 years of menarche; failure to establish regular cycles by then is itself a diagnostic signal.

Hyperandrogenism can be established either clinically or biochemically, and either is sufficient. Clinical hyperandrogenism means visible signs of elevated androgen activity: hirsutism (excess terminal hair in a male-pattern distribution, most commonly the face, neck, chest, and lower abdomen), persistent acne beyond adolescence (typically cystic and inflammatory), or female pattern hair loss (thinning along the central scalp parting). Hirsutism is typically scored using the modified Ferriman-Gallwey scale, with a score of 4 to 6 considered mild, and higher scores progressively more significant. Biochemical hyperandrogenism means elevated total testosterone, free androgen index (FAI), or dehydroepiandrosterone sulfate (DHEAS) on blood testing. In practice, both are usually assessed together — a woman may have clinical signs without markedly elevated blood levels, or elevated blood levels with subtle clinical signs.

Polycystic ovarian morphology on transvaginal ultrasound is defined in the 2023 Guideline as twenty or more follicles per ovary in at least one ovary, or an ovarian volume greater than 10 mL4. The threshold of twenty is higher than the previous threshold of twelve — it reflects improvements in ultrasound resolution that would otherwise cause over-diagnosis. For women who cannot have a transvaginal ultrasound (adolescents, unmarried women, women who prefer not to), transabdominal ultrasound is used, but with different thresholds. AMH — anti-Müllerian hormone — is a blood marker of follicle count and can be used as a surrogate for ultrasound morphology when imaging is not available or not diagnostic.

Any two of these three features, in the absence of other causes, establishes the PMOS diagnosis.

Diagnosis in adolescents

Diagnosing PMOS in adolescents is deliberately more conservative than in adults, for one reason: adolescent ovaries commonly show polycystic morphology on ultrasound even in the absence of PMOS. Follicles are more abundant in the years around menarche; using the adult ultrasound criterion in an adolescent would produce false-positive diagnoses at scale.

The 2023 International Guideline therefore excludes ovarian morphology as a diagnostic criterion in adolescents. Diagnosis in this age group requires both ovulatory dysfunction and hyperandrogenism — the two clinical criteria, without the imaging feature. The AMH threshold is also different in adolescents, and AMH is used with caution.

Even with these more conservative criteria, adolescent diagnosis is often deferred rather than made definitively. If a fifteen-year-old presents with irregular cycles and mild hirsutism, the appropriate approach is often to record the pattern, initiate metabolic evaluation and lifestyle counselling, treat symptoms as needed, and reassess in one to two years. Many adolescents whose cycles are irregular in the first two to three years after menarche establish regular cycles later and do not have PMOS. Others do have PMOS and the diagnosis becomes clearer as they mature.

The clinical implication is that a definite PMOS diagnosis in an adolescent should be made only when the pattern is clear. A provisional or deferred diagnosis is perfectly reasonable, and does not deny the young woman appropriate care in the meantime. Metabolic evaluation, lifestyle interventions, and symptom management can proceed while the formal diagnosis is held open.

The Full Workup

A complete PMOS evaluation is more than one or two blood tests and an ultrasound. Done properly, it involves several coordinated components, each answering a specific diagnostic question.

Clinical history. Cycle pattern from menarche onward, pubertal development, weight trajectory, family history of PMOS, type 2 diabetes, or cardiovascular disease, current symptoms, medications, and reproductive plans. This is often more diagnostically valuable than any single test.

Physical examination. Body composition and central adiposity, hirsutism scoring, examination for acanthosis nigricans (a marker of significant insulin resistance), assessment of thyroid, and blood pressure.

Hormonal panel. Total testosterone, sex hormone-binding globulin (SHBG) with calculated free androgen index, DHEAS, 17-hydroxyprogesterone (to rule out congenital adrenal hyperplasia), prolactin, thyroid-stimulating hormone (TSH), and AMH. Some centres add LH and FSH; these are less diagnostically decisive than the androgens but can be informative.

Metabolic panel. The 2023 International Guideline recommends a 75-gram oral glucose tolerance test (OGTT) in almost all women with PMOS at diagnosis — not simply fasting glucose or HbA1c, but the full OGTT with 2-hour post-glucose measurement. This is because glucose intolerance often precedes overt diabetes by years and is missed on fasting tests alone. In addition: fasting insulin, HbA1c, and a full lipid profile (total cholesterol, LDL, HDL, triglycerides).

Imaging. Transvaginal ultrasound (or transabdominal in adolescents and unmarried women) to assess ovarian morphology, ovarian volume, and to exclude other pelvic pathology.

Mental health screening. The 2023 International Guideline formally recommends screening for depression and anxiety at diagnosis. This can be done with brief validated instruments such as the PHQ-9 and GAD-7. Where positive, appropriate referral or management follows.

Each of these components answers a specific diagnostic question. The hormonal panel identifies hyperandrogenism and excludes look-alike conditions. The metabolic panel establishes the baseline metabolic profile against which future care will be measured. The imaging identifies the ovarian morphology feature. The mental health screening identifies the psychological dimension that is now part of standard PMOS care.

The Exclusion Diagnoses

PMOS is a diagnosis of pattern recognition in the absence of alternative causes. Several other conditions can produce features that overlap with PMOS, and each must be considered and excluded before the diagnosis is made.

Congenital adrenal hyperplasia. Particularly the non-classic form, which can present in adolescence or adulthood with hyperandrogenism and irregular cycles that closely mimic PMOS. Excluded by measuring 17-hydroxyprogesterone; an elevated result triggers further evaluation.

Androgen-secreting tumours of the ovary or adrenal. Rare but important, because they present with rapid-onset or severe virilisation rather than the gradual pattern of PMOS. Very high testosterone or DHEAS levels warrant imaging to look for a tumour.

Thyroid dysfunction. Hypothyroidism in particular can produce cycle irregularity and metabolic changes that overlap with PMOS. TSH is part of the standard workup.

Hyperprolactinaemia. Elevated prolactin can suppress ovulation and produce irregular cycles. Prolactin is measured.

Cushing’s syndrome. Rare but can present with central weight gain, hirsutism, and irregular cycles. Suspected on clinical grounds; specific testing follows if suspected.

Excluding these conditions is why the standard workup includes 17-hydroxyprogesterone, prolactin, and TSH alongside the androgens. Skipping the exclusion tests risks a wrong diagnosis and, more importantly, missing a treatable alternative condition.

PMOS Phenotypes

Because PMOS is diagnosed on any two of three features, four distinct combinations can produce the diagnosis. These are formally described as phenotypes A, B, C, and D:

Phenotype A. All three features present: ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology. This is the classical or full phenotype and typically the most metabolically affected. Women with phenotype A have the highest rates of insulin resistance, metabolic syndrome, and long-term cardiovascular risk.

Phenotype B. Ovulatory dysfunction and hyperandrogenism, without polycystic ovarian morphology. Similar metabolic profile to phenotype A.

Phenotype C. Hyperandrogenism and polycystic ovarian morphology, with apparently regular cycles. Sometimes described as ovulatory PMOS. Milder metabolic profile than A or B, though still elevated compared with women without PMOS.

Phenotype D. Ovulatory dysfunction and polycystic ovarian morphology, without hyperandrogenism. The least metabolically severe phenotype.

In the Indian context, the ICMR National PCOS Task Force found that phenotype C is the most common phenotype at 40.8 percent5 — meaning that a substantial proportion of Indian women with PMOS have apparently regular cycles and would be missed by a workup that begins and ends with cycle history. This is one of the most important practical consequences of the ICMR data: PMOS evaluation in Indian women must include hormonal and imaging assessment from the outset, not defer them to the case of an irregular cycle.

Phenotype has clinical implications: it influences long-term risk profile, response to certain treatments, and the intensity of monitoring warranted.

What a Good Diagnostic Visit Looks Like

A well-done PMOS diagnostic evaluation typically takes place over two visits, with the workup between them.

At the first visit, the clinician takes a detailed history, performs a physical examination, and orders the appropriate blood tests and imaging. This visit typically takes 30 to 45 minutes. The clinician should discuss what is being investigated and why, and should tell you when the results will be reviewed.

The blood tests and imaging are done in the days that follow. Some tests — the OGTT, for example — require specific preparation and are done in the morning after an overnight fast.

At the second visit, the clinician reviews the results with you. This visit is where the diagnosis is either made, provisionally made pending further information, or excluded. If PMOS is diagnosed, the clinician should explain which phenotype, discuss the treatment options relevant to your situation, and outline a follow-up plan. This visit typically also takes 30 to 45 minutes.

A well-done diagnostic conversation covers not just the diagnosis but the treatment framework, the long-term implications, the mental-health dimension, and your specific priorities — whether fertility, symptom relief, cardiometabolic protection, or general health. It is a conversation, not a pronouncement.

If your diagnostic evaluation was substantially briefer than this, or if the results were communicated by message without discussion, it may be worth requesting a follow-up conversation to walk through the findings and the plan properly.

The Pattern, Not Any Single Test

The most important thing to understand about PMOS diagnosis is that it is pattern recognition, not test-checking. No single blood test, no single ultrasound finding, and no single symptom is diagnostic on its own. The diagnosis is made when a clinician sees the pattern in the full evaluation and confirms that no alternative condition better explains it.

This means that being told your ultrasound shows polycystic ovaries is not the same as being told you have PMOS. It means that a normal testosterone level does not by itself rule out the diagnosis. It means that regular cycles do not rule out the diagnosis either — as the phenotype C data show.

If you are being evaluated, ask for the full workup. If you have already been evaluated and are unclear on where things stand, ask for a follow-up conversation to walk through the pattern. That is what the visit is for.

For the broader clinical picture of PMOS and what the diagnosis implies for treatment, see the pillar article Understanding PMOS.

About the Author

Dr Rajeev Daftary is a senior consultant at Aksigen IVF, with clinical focus on reproductive endocrinology, diagnostic evaluation of infertility, and the metabolic dimensions of PMOS and related conditions.

This article is part of the Bharat Daftary Knowledge Centre, the patient-education programme of Aksigen IVF. It is intended for general information and does not replace consultation with a qualified clinician.

References

Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, et al., on behalf of the International PCOS Network. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Human Reproduction. 2023;38(9):1655–1679. DOI: 10.1093/humrep/dead156.
Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. Published online May 12, 2026.
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility. 2004;81(1):19–25.
Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, Escobar-Morreale HF. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update. 2014;20(3):334–352.
Ganie MA, Chowdhury S, Suri V, Joshi B, Bhattacharya PK, Agrawal S, et al. Prevalence, phenotypes, and comorbidities of polycystic ovary syndrome among Indian women. JAMA Network Open. ICMR-PCOS National Task Force, n = 9,824.

Aksigen IVF•Bharat Daftary Knowledge Centre•How PMOS is diagnosed today, v1.0•June 2026